Screening for type 2 diabetes and impaired glucose metabolism

被引:77
作者
Colagiuri, S
Hussain, Z
Zimmet, P
Cameron, A
Shaw, J
机构
[1] Prince Wales Hosp, Dept Diabet Endocrinol & Metab, Randwick, NSW 2031, Australia
[2] Int Diabet Inst, Caulfield, Vic, Australia
关键词
D O I
10.2337/diacare.27.2.367
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To assess the Australian protocol for identifying undiagnosed type 2 diabetes and impaired glucose metabolism. Research Design and Methods-The Australian screening protocol recommends a stepped approach to detecting undiagnosed type 2 diabetes based on assessment of risk status, measurement of fasting plasma glucose (FPG) in individuals at risk, and further testing according to FPG. The performance of and variations to this protocol were assessed in a population-based sample of 10,508 Australians. Results-The protocol had a sensitivity of 79.9%, specificity of 79.9%, and a positive predictive value (PPV) of 13.7% for detecting undiagnosed type 2 diabetes and sensitivity of 51.9% and specificity of 86.7% for detecting impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). To achieve these diagnostic rates, 20.7% of the Australian adult population would require an oral glucose tolerance test (OGTT). Increasing the FPG cut point to 6.1 mmol/l (110 mg/dl) or using HbA(1c) instead of FPG to determine the need for an OGTT in people with risk factors reduced sensitivity, increased specificity and PPV, and reduced the proportion requiring an OGTT. However, each of these protocol variations substantially reduced the detection of IGT or IFG. Conclusions-The Australian screening protocol identified one new case of diabetes for every 32 people screened, with 4 of 10 people screened requiring FPG measurement and 1 in 5 requiring an OGTT. In addition, 1 in 11 people screened had IGT or IFG. Including HbA(1c) measurement substantially reduced both the number requiring an OGTT and the detection of IGT or IFG.
引用
收藏
页码:367 / 371
页数:5
相关论文
共 19 条
[1]  
*AM DIAB ASS, 1993, DIABETES FORECAST, V46, P54
[2]  
*AM DIAB ASS, 2003, DIABETES CARE S1, V26, pS21, DOI DOI 10.2337/DIACARE.26.2007.S21
[3]  
[Anonymous], 1999, WHONCDNCS992
[4]   Performance at a predictive model to identity undiagnosed diabetes in a health care setting [J].
Baan, CA ;
Ruige, JB ;
Stolk, RP ;
Witteman, JCM ;
Dekker, JM ;
Heine, RJ ;
Feskens, EJM .
DIABETES CARE, 1999, 22 (02) :213-219
[5]   The prevalence of diabetes in the Kingdom of Tonga [J].
Colagiuri, S ;
Colagiuri, R ;
Na'ati, S ;
Muimuiheata, S ;
Hussain, Z ;
Palu, T .
DIABETES CARE, 2002, 25 (08) :1378-1383
[6]  
Colagiuri S, 2002, EVIDENCE BASED GUIDE
[7]  
*DIAB PREV PROGR R, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]
[8]   The rising prevalence of diabetes and impaired glucose tolerance - The Australian diabetes, obesity and lifestyle study [J].
Dunstan, DW ;
Zimmet, PZ ;
Welborn, TA ;
de Courten, MP ;
Cameron, AJ ;
Sicree, RA ;
Dwyer, T ;
Colagiuri, S ;
Jolley, D ;
Knuiman, M ;
Atkins, R ;
Shaw, JE .
DIABETES CARE, 2002, 25 (05) :829-834
[9]   The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) - methods and response rates [J].
Dunstan, DW ;
Zimmet, PZ ;
Welborn, TA ;
Cameron, AJ ;
Shaw, J ;
de Courten, M ;
Jolley, D ;
McCarty, DJ .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2002, 57 (02) :119-129
[10]   Screening for type 2 diabetes [J].
Engelgau, MM ;
Narayan, KMV ;
Herman, WH .
DIABETES CARE, 2000, 23 (10) :1563-1580